temozolomide

You have access
Magnolol Traverses the Blood-brain Barrier and Enhances Temozolomide-induced Intrinsic Apoptosis of Glioblastoma Cells via a p53 Redox Signaling Mechanism
GONG-JHE WU, JUI-TAI CHEN, SHING-HWA LIU, EDWIN CHEN and RUEI-MING CHEN

Anticancer Research November 2025, 45 (11) 5001-5017; DOI: https://doi.org/10.21873/anticanres.17842
Open Access
Effects of Azelastine on Glioblastoma Cells
YUKI UEMICHI, SEINA YASUDA, MIYUKI MABUCHI, SHUHEI NAKAO, SHUJI NAGANO and TADASHI SHIMIZU

Anticancer Research July 2025, 45 (7) 2763-2771; DOI: https://doi.org/10.21873/anticanres.17645
Open Access
Sex-related Survival Differences in Patients With Glioblastoma – Results From a Retrospective Analysis
JAN LEPPERT, CLAUDIA DITZ, JAKOB MATSCHKE, HARALD KRENZLIN, NAUREEN KERIC, CHRISTIAN ZIEMANN, LORENZ HAHN, MARIA VITTORIA MATONE, LARYSA LIUBICH, KAROLIN STREUBEL, HANNES SCHACHT, CHRISTINA HILLBRICHT, PATRICK KUPPLER, DIRK RADES and ANASTASSIA LÖSER

Anticancer Research May 2025, 45 (5) 2059-2069; DOI: https://doi.org/10.21873/anticanres.17580
You have access
Effects of Lomerizine and Its Metabolite on Glioblastoma Cells
YUKI UEMICHI, MIYUKI MABUCHI, NATSUMI TSUCHIYA, SEINA YASUDA, SHUHEI NAKAO and TADASHI SHIMIZU

Anticancer Research July 2024, 44 (7) 2943-2952; DOI: https://doi.org/10.21873/anticanres.17106
You have access
Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment
SAMUEL D. LUSTIG, SRAVAN K. KODALI, SHARON L. LONGO, SOMANATH KUNDU and MARIANO S. VIAPIANO

Anticancer Research February 2022, 42 (2) 723-730; DOI: https://doi.org/10.21873/anticanres.15530
You have access
Multiparametric MRI-guided Hypofractionated Intensity-modulated Radiation Therapy With Simultaneous Integrated Boost for Glioblastoma
YUKIHIRO HAMA and ETSUKO TATE

Anticancer Research January 2022, 42 (1) 329-334; DOI: https://doi.org/10.21873/anticanres.15489
You have access
Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug – Comparison With the Chemotherapeutic Standard-of-care Temozolomide
AKIRA SUMIYOSHI, SAYAKA SHIBATA, ZHIVKO ZHELEV, THOMAS MILLER, DESSISLAVA LAZAROVA, GENOVEVA ZLATEVA, ICHIO AOKI and RUMIANA BAKALOVA

Anticancer Research December 2021, 41 (12) 6067-6076; DOI: https://doi.org/10.21873/anticanres.15426
You have access
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells
YUN CHEN, BOR-JIUN TSENG, YA-HUI TSAI and SHENG-HONG TSENG

Anticancer Research September 2020, 40 (9) 5141-5149; DOI: https://doi.org/10.21873/anticanres.14517
You have access
Human Glioma Cells Acquire Temozolomide Resistance After Repeated Drug Exposure Via DNA Mismatch Repair Dysfunction
KEI YAMASHIRO, KAZUTAKA NAKAO, SHIGEO OHBA and YUICHI HIROSE

Anticancer Research March 2020, 40 (3) 1315-1323; DOI: https://doi.org/10.21873/anticanres.14073
You have access
Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth
MANA INADA, AKIRA SATO, MIKA SHINDO, YOHEI YAMAMOTO, YASUHARU AKASAKI, KOICHI ICHIMURA and SEI-ICHI TANUMA

Anticancer Research December 2019, 39 (12) 6743-6750; DOI: https://doi.org/10.21873/anticanres.13889

Main menu

User menu

Search

temozolomide

Pages